{
    "clinical_study": {
        "@rank": "136128", 
        "arm_group": [
            {
                "arm_group_label": "Epirubicin-cyclophosphamide-S-1( ECS)", 
                "arm_group_type": "Experimental", 
                "description": "S-1(SuLi,QILU Pharmaceutical co.ltd ) was  given at  a  standard  dose  of 40 mg/m2 twice daily in  cycles  of 14-day  consecutive administration followed by  a  14-day  rest, combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly."
            }, 
            {
                "arm_group_label": "Epirubicin-cyclophosphamide-5-FU (ECF)", 
                "arm_group_type": "Active Comparator", 
                "description": "5-FU was  given at  a  standard  dose  of 500mg/m2 (infusion, d1, d8 respectively), combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly."
            }
        ], 
        "brief_summary": {
            "textblock": "S-1 is  a  newly developed novel oral  dihydrouracil dehydrogenase inhibiting\n      fluoro-pyrimidine drug consisting of i  M tegafur (FT), 0.4 M 5-chloro-2,\n      4-dihydroxypyrimidine (gimeracil), and 1 M potassium oxonate (oteracil),  with efficient\n      antitumor activity and low gastrointestinal toxicity. Several studies have proved the safety\n      and efficacy of single agent S-1 in metastatic breast cancer. This study is designed to\n      further investigate and compare the efficacy and safety of\n      Epirubicin-cyclophosphamide-S-1(ECS) vs. Epirubicin-cyclophosphamide-5-fluorouracil (ECF) as\n      neoadjuvant chemotherapy in patients with local advanced breast cancer."
        }, 
        "brief_title": "Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Neoplasms", 
            "Neoadjuvant Therapy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Disease characteristic:\n\n               -  Histologically confirmed primary breast cancer by core biopsy (Mammotome or\n                  bard needle)\n\n               -  Disease stage appropriate for neoadjuvant chemotherapy (T\u22653cm, N0 or T\uff082-3cm\uff09N1\n                  or any T, N2)\n\n               -  Her-2(-); Ki67\u226514%\n\n               -  No previous treatment for breast cancer (chemotherapy, endocrinotherapy,\n                  radiotherapy)\n\n          -  Patients characteristic:\n\n               -  Female patients, age 18 to 70 years old\n\n               -  Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-2\n\n               -  Life expectancy of at least 12 weeks\n\n               -  Willing to be kept follow-up\n\n               -  Functions below are maintained in major organs:\n\n               -  Cardiac status:\n\n        LVEF: 50% 45% \u2022 Haematopoietic status: Leukocyte count: \u22654.0\u00d7109/L Neutrophil count:\n        \u22652.0\u00d7109/L Platelet count: \u2265100\u00d7109/L Hemoglobin: \u226580g/L\n\n        \u2022 Hepatic status: Total Bilirubin \u2264 1.5 x upper limit of normal (ULN), AST and ALT \u2264 2.5\n        times ULN(no liver metastasis) bilirubin:\n\n        \u2022 Renal status: BUN \u2264 1.5 x times ULN Creatinine \u22641.5 times ULN or calculated creatinine\n        clearance, using the Cockcroft-Gault formula, \u226550 mL/min; Women's Ccr = Body weight x\n        (140-Age)/(72 x Serum creatinine) x 0.85\n\n        \u2022 Written informed consent (both biopsy and neoadjuvant chemotherapy) will be obtained for\n        patients for entering this study\n\n        Exclusion Criteria:\n\n          -  Previous treatment for breast cancer (neither local nor systemic therapy)\n\n          -  Known or suspected distant metastasis\n\n          -  Potentially pregnant, pregnant, or breast-feeding\n\n          -  Drug allergy\n\n          -  Concurrent malignancy or history of other malignancy (except Hodgkin lymphoma)\n\n          -  Currently active severe infection (Hepatitis included)\n\n          -  History of significant neurological or psychiatric disorders including psychotic\n             disorders, dementia or seizures\n\n          -  Known history of uncontrolled severe heart disease, myocardial infarction within 6\n             months, congestive heart failure, unstable angina pectoris, clinically significant\n             hydropericardium or unstable arrhythmias"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01849380", 
            "org_study_id": "BEST T-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Epirubicin-cyclophosphamide-S-1( ECS)", 
                "description": "S-1(SuLi, QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration", 
                "intervention_name": "S-1", 
                "intervention_type": "Drug", 
                "other_name": "SuLi, QILU Pharmaceutical co.ltd"
            }, 
            {
                "arm_group_label": "Epirubicin-cyclophosphamide-5-FU (ECF)", 
                "description": "5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively),", 
                "intervention_name": "5-FU", 
                "intervention_type": "Drug", 
                "other_name": "5-FU"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Fluorouracil", 
                "Epirubicin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Local Advanced Breast Neoplasms", 
            "Neoadjuvant Chemotherapy", 
            "S-1"
        ], 
        "lastchanged_date": "May 6, 2013", 
        "location": {
            "contact": {
                "email": "yzg@medmail.com.cn", 
                "last_name": "Gang Z Yu, Dr; PhD", 
                "phone": "+86 0531-85875048"
            }, 
            "facility": {
                "address": {
                    "city": "Jinan", 
                    "country": "China", 
                    "state": "Shandong", 
                    "zip": "250033"
                }, 
                "name": "the Second Hospital of Shandong Universtity"
            }, 
            "investigator": {
                "last_name": "Gang Z Yu, Dr; PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Neoadjuvant Epirubicin-cyclophosphamide-S-1 (ECS) Versus Epirubicin-cyclophosphamide-5-FU (ECF) in Local Advanced Breast Cancer", 
        "overall_contact": {
            "email": "yzg@medmail.com.cn", 
            "last_name": "Gang Z Yu, Dr; PhD", 
            "phone": "+86 0531-85875048"
        }, 
        "overall_official": {
            "affiliation": "the second hospital of Shandong University", 
            "last_name": "Gang Z Yu, Dr; PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pathological complete response (pCR=ypT0 ypN0) rates of neoadjuvant treatment No microscopic evidence of residual invasive or non-invasive viable tumor cells in all resected specimens of the breast and axilla.\nPathological response will be assessed considering all removed breast and lymphatic tissues from all surgeries.\nThe primary endpoint will be summarized as pathological complete remission rate for each treatment group.\nUltrasonic examination will be performed every 2 cycles of treatment for efficacy evaluation.", 
            "measure": "Pathological complete response", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01849380"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shandong University", 
            "investigator_full_name": "Yu-Zhi Gang", 
            "investigator_title": "Director of Department of Breast Disease", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer.\nEvaluation will be performed every 2 cycles of treatment during therapy, and follow-up will be performed every 3 months after therapy", 
                "measure": "Disease-free Survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Reference to NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v 3.0. The endpoint will be summarized as events rate (%) for each treatment group", 
                "measure": "Tolerability and safety", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Shandong University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shandong University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}